Cempra Pharmaceuticals announced positive results from its Phase 2 trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of Taksta (sodium fusidate) for patients suffering from acute bacterial skin and skin structure infections (ABSSSI). In this double-blind randomized study, 198 patients were assigned to one of the treatment arms. Drug administration was for 10-14 days. This study demonstrated efficacy comparable to linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI) indicating that Taksta will have a high probability of demonstrating non-inferiority vs. linezolid in pivotal Phase 3 trials.
Taksta, formerly known as CEM-102, is an oral antibiotic being developed in the United States for the treatment of staphylococcal infections including hospital-acquired methicillin-resistant Staphylococcus aureus (HA-MRSA) and community-acquired MRSA (CA-MRSA).
For more information call (919) 467-1716 or visit www.cempra.com.